Skip to main content
Hyloris Pharmaceuticals SA logo

Hyloris Pharmaceuticals SA — Investor Relations & Filings

Ticker · HYL ISIN · BE0974363955 LEI · 875500LZIWS7QEQE0I73 BR Manufacturing
Filings indexed 259 across all filing types
Latest filing 2026-05-08 Regulatory Filings
Country BE Belgium
Listing BR HYL

About Hyloris Pharmaceuticals SA

https://hyloris.com/

Hyloris Pharmaceuticals SA is a specialty biopharma company focused on innovating, reinventing, and optimizing existing medications to address unmet medical needs. The company's strategy centers on reformulating and repurposing established drugs to create value-added medicines for patients, healthcare professionals, and payors. By utilizing established regulatory pathways, such as the FDA's 505(b)(2) process, Hyloris aims to reduce development timelines, costs, and risks. The company has built a broad, patented portfolio of product candidates. Its commercialized products include Sotalol IV for the treatment of atrial fibrillation and Maxigesic® IV, a non-opioid for post-operative pain. In addition to its core focus, Hyloris also develops and commercializes high-barrier generic products.

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.